|By Business Wire||
|January 3, 2014 10:19 AM EST||
CEO Cynthia (Dohmen) LaConte announced today that Dohmen has acquired three technology companies; Red Arrow Labs, Clinical Path Consulting and ChemWare. Founder of two of the companies, Mark Grosskopf will join Dohmen as the CIO of Dohmen Life Science Services and will continue to serve as president of all three companies going forward.
LaConte said Dohmen began searching for best practice technology companies to expand its offering to clients in the areas of applications development, data analytics, consulting services and hosting. “Our life science and healthcare clients are increasingly interested in using technology to connect with and empower healthcare consumers; in particular, through the growing use of analytics and mobile applications.”
LaConte added that the companies’ shared values and unique mix of services played a key role in Dohmen’s decision to move forward with the acquisitions. “We wanted to bring valuable new skills to our clients, and these companies will do that. Red Arrow designs and develops unique applications, Clinical Path Consulting provides regulatory and IT advisory services to healthcare providers, and ChemWare offers critical information management solutions to the laboratory market. But we also wanted to find that new capability rooted in a common culture; one that operates from a place of purpose and trust.”
Grosskopf said he shares LaConte’s enthusiasm regarding the companies’ blend of shared values and purpose. “It’s exciting to join forces with a solid, privately held company that shares our goal of leveraging technology to create efficiencies within healthcare while making a real difference in peoples' lives by improving the quality of their care.”
Founded in 1858, Dohmen is an outsourced services company dedicated to improving the lives of others by supplying the treatments and tools they need to live healthier lives.
As the trusted partner to more than 600 BioPharma and MedTech innovators, through DLSS, Dohmen powers start-up, mid-tier and Fortune 500 companies with support services that span the commercialization continuum from pre-approval regulatory consulting to in-home patient services. Privately held and conflict free, Dohmen is uniquely positioned to propel personalized healthcare for life science innovators and individuals.